Gilead Sciences News - July 2026

Gilead Nears EU Approval for Trodelvy, Cutting Progression Risk 35%

Gilead Sciences received a positive opinion from the European Medicines Agency’s expert panel for its drug Trodelvy. The Committee for Medicinal Products for...

🔴 Gilead Sciences drops after failed Phase 3 solid tumor trial

Gilead Sciences is trading at $129.30 (4.1% down) today following the announcement of a failed Phase 3 solid tumor clinical trial. • The decline also comes...